Hi Phaedrus- have sent Pledge into oblivion- cannot abide such...

First 79 Last

Share
Profile

Follow
reginaldp

3,070 Posts.

2171

26/03/24

13:52

Post #: 73063949
Share

Originally posted by Phaedrus: ↑

Hi Reg,

yes, you're right we're still 'not there yet'. But I'd submit the 'remaining issues' language is a reference to the outstanding CRL, which needs a formal response. In any case, I'd see it as a normal reservation to have while we are step-wise following SOPP processes, & IMO it doesn't translate necessarily as 'problem'.

I agree that, for you and me, the characterization issues that 'remain' could use more definition. But it may also simply be e.g. that Klinker doesn't want to be seen as as rubber stamp, and wants his role to be respected. OK. He comes back into the process after a CRL which listed 'product characterisation' issues as TBA. He can say 'yes, it looks good, but we need a) the formal documentation and b) time to check all the data you've provided'.

I don't see how the FDA can invite the resubmission of a BLA while these issues are so problematic that they can't be resolved during the resubmission process. Perhaps they (FDA) simply need a little more time to digest fully the data, but - on the strength of what they have seen - are prepared to do so in tandem with the preparation for filing and consideration of the resubmission of the BLA itself. Remember, the FDA's intended Review Team members would have been in attendance at this meeting, under the terms of PDUFA VII.

BTW, the signoff on potency assays and potency assurance strategies means IMO that the adult trial can now go ahead. Expect more announcements.

Think happy thoughts. If nothing else happens this year, its still going to be my shout for those oysters we're going to be consuming at the AGM after-party.

You can buy the beers.

Everyone should DYOR, of course.

Expand

Hi Phaedrus- have sent Pledge into oblivion- cannot abide such distasteful commentary.

YES - Adult potency assay would probably be announced on receipt of FDA minutes 23/04/2024 ish

What is it with this stock that everything takes so damn long?

Reg

MSB Price at posting: 42.8¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

SGP

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

PAM

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

RAD

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

There are more pages in this discussion • 1,018 more messages in this thread...

First 79 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.61		Change 0.030(1.90%)		Mkt cap ! $1.832B

Open	High	Low	Value	Volume
$1.65	$1.65	$1.59	$7.014M	4.343M

Buyers (Bids)

No.	Vol.	Price($)
1	342	$1.61

Sellers (Offers)

Price($)	Vol.	No.
$1.61	54534	8

View Market Depth

No.	Vol.	Price($)
1	342	1.605
4	30338	1.595
8	115113	1.590
10	104197	1.585
11	72127	1.580

Price($)	Vol.	No.
1.610	54534	8
1.615	38708	1
1.620	66509	6
1.625	53872	5
1.630	51734	4

Last trade - 16.10pm 19/11/2024 (20 minute delay)

MSB (ASX) Chart

Hi Phaedrus- have sent Pledge into oblivion- cannot abide such...

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi Phaedrus- have sent Pledge into oblivion- cannot abide such...

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News